Over the last 2 years, our therapeutic armamentarium against genomically-defined subgroups of non-small cell lung cancer (NSCLC) has extended to patients with acquired resistance to front-line targeted therapy. Alectinib (Alecensa®, CH5424802), a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK), is indicated for patients with metastatic, ALK rearrangement-positive NSCLC whose disease has worsened after treatment with crizotinib or who became intolerant of the drug and it received orphan drug designation, breakthrough therapy designation, priority review status, and accelerated approval by the FDA.
from Cancer via ola Kala on Inoreader http://ift.tt/2bY6TAK
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου